Burkitt Lymphoma
"Burkitt Lymphoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
Descriptor ID |
D002051
|
MeSH Number(s) |
C02.256.466.313.165 C02.928.313.165 C04.557.386.480.100 C04.557.386.480.150.165 C04.619.935.313.165 C04.925.313.165 C15.604.515.569.480.100 C15.604.515.569.480.150.165 C20.683.515.761.480.100 C20.683.515.761.480.150.165
|
Concept/Terms |
Burkitt Lymphoma- Burkitt Lymphoma
- Lymphoma, Burkitt
- Burkitt's Tumor
- Burkitts Tumor
- Tumor, Burkitt's
- Burkitt Tumor
- Tumor, Burkitt
- Burkitt Cell Leukemia
- Cell Leukemia, Burkitt
- Leukemia, Burkitt Cell
- Burkitt Leukemia
- Leukemia, Burkitt
- Leukemia, Lymphoblastic, Burkitt-Type
- Leukemia, Lymphocytic, L3
- Lymphocytic Leukemia, L3
- L3 Lymphocytic Leukemia
- L3 Lymphocytic Leukemias
- Leukemia, L3 Lymphocytic
- Leukemias, L3 Lymphocytic
- Lymphocytic Leukemias, L3
- Burkitt's Lymphoma
- Burkitts Lymphoma
- Lymphoma, Burkitt's
- Burkitt's Leukemia
- Burkitts Leukemia
- Leukemia, Burkitt's
|
Below are MeSH descriptors whose meaning is more general than "Burkitt Lymphoma".
Below are MeSH descriptors whose meaning is more specific than "Burkitt Lymphoma".
This graph shows the total number of publications written about "Burkitt Lymphoma" by people in UAMS Profiles by year, and whether "Burkitt Lymphoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2023 | 2 | 0 | 2 | 2021 | 1 | 0 | 1 | 2019 | 1 | 1 | 2 | 2017 | 1 | 0 | 1 | 2015 | 2 | 0 | 2 | 2014 | 1 | 0 | 1 | 2012 | 1 | 0 | 1 | 2011 | 1 | 0 | 1 | 2010 | 1 | 0 | 1 | 2009 | 1 | 0 | 1 | 2008 | 2 | 0 | 2 | 2006 | 1 | 0 | 1 | 2005 | 2 | 2 | 4 | 2004 | 1 | 0 | 1 | 2003 | 2 | 0 | 2 | 2002 | 0 | 1 | 1 | 1995 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Burkitt Lymphoma" by people in Profiles over the past ten years.
-
McNerney KO, Moskop A, Winestone LE, Baggott C, Talano JA, Schiff D, Rossoff J, Modi A, Verneris MR, Laetsch TW, Schultz L. Practice Preferences for Consolidative Hematopoietic Stem Cell Transplantation Following Tisagenlecleucel in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2024 Jan; 30(1):75.e1-75.e11.
-
Bomken S, Enshaei A, Schwalbe EC, Mikulasova A, Dai Y, Zaka M, Fung KTM, Bashton M, Lim H, Jones L, Karataraki N, Winterman E, Ashby C, Attarbaschi A, Bertrand Y, Bradtke J, Buldini B, Burke GAA, Cazzaniga G, Gohring G, De Groot-Kruseman HA, Haferlach C, Nigro LL, Parihar M, Plesa A, Seaford E, Sonneveld E, Strehl S, Van der Velden VHJ, Rand V, Hunger SP, Harrison CJ, Bacon CM, Van Delft FW, Loh ML, Moppett J, Vormoor J, Walker BA, Moorman AV, Russell LJ. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement. Haematologica. 2023 03 01; 108(3):717-731.
-
Hoover A, Zimmerman JAO, Wiese S, Modi A. Evaluation of Empiric Vancomycin for Fevers During High-dose Cytarabine Administration. J Pediatr Hematol Oncol. 2021 Oct 01; 43(7):e1010-e1014.
-
Wang L, Howell MEA, Sparks-Wallace A, Hawkins C, Nicksic CA, Kohne C, Hall KH, Moorman JP, Yao ZQ, Ning S. p62-mediated Selective autophagy endows virus-transformed cells with insusceptibility to DNA damage under oxidative stress. PLoS Pathog. 2019 04; 15(4):e1007541.
-
Gao Y, Wang L, Lei Z, Li J, Forrest JC, Liang X. IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells. J Gen Virol. 2019 05; 100(5):851-862.
-
Mukhtar F, Boffetta P, Risch HA, Park JY, Bubu OM, Womack L, Tran TV, Zgibor JC, Luu HN. Survival predictors of Burkitt's lymphoma in children, adults and elderly in the United States during 2000-2013. Int J Cancer. 2017 04 01; 140(7):1494-1502.
-
Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnston N, Kaplan L. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015 Jul 09; 126(2):160-6.
-
Shiramizu B, Goldman S, Smith L, Agsalda-Garcia M, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Barth MJ, Mussolin L, Cairo MS. Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report. Br J Haematol. 2015 Aug; 170(3):367-71.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|